Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
NCT ID: NCT01482585
Last Updated: 2011-11-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2011-10-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
early stage lung adenocarcinoma
CT, PET, copy number alteration
Duel-energy CT, PET, copy number alteration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CT, PET, copy number alteration
Duel-energy CT, PET, copy number alteration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* B. Newly-diagnosed Stage I or II from the clinical work up including PET/CT
* C. Performance status of 0 to 1 on the ECOG scale
* D. Age 20 years or older
* E. Able to tolerable DECT imaging required by protocol
* F. Able to give study-specific informed consent
Exclusion Criteria
* B. planning of Definitive RTx 나 neoadjuvant CCRTx
* C. Poor cardiopulmonary reserve
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korean Foundation for Cancer Research
UNKNOWN
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Young Mog Shim, Dr.
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lee
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMC 2011-09-083
Identifier Type: -
Identifier Source: org_study_id